A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

Part of paid clinical trials in Chula Vista, California.

Sponsor
Jade Biosciences, Inc.
Study ID
NCT07541287
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • JADE101 — DRUG
    JADE101 is supplied as sterile solution to be administered by SC injection

Study Details

This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.

Key Dates

Start date
May 19, 2026
Status verified
May 2026
Primary completion
Jan 31, 2029
Completion
Apr 30, 2029

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: JADE101
    Subcutaneous (SC) injection of JADE101

Primary Outcome Measure

Incidence of treatment-emergent adverse events (safety and tolerability) [ Time Frame: Day 1 through 100 weeks ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
Jade Clinical SiteChula VistaCalifornia91910-
Jade Clinical SiteArvadaColorado80002-
Jade Clinical SiteDenverColorado80220-
Jade Clinical SiteOrlandoFlorida32806-
Jade Clinical SitePembroke PinesFlorida33029-
Jade Clinical SiteHoustonTexas77099-

Find similar trials in Chula Vista, CA

By research site
Jade Clinical Site· Chula Vista, CAJade Clinical Site· Arvada, COJade Clinical Site· Denver, COJade Clinical Site· Orlando, FLJade Clinical Site· Pembroke Pines, FLJade Clinical Site· Houston, TX

Related Studies